M. Koller

发表

Evaluation of smartphone‐based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial

Anirvan Ghosh, A. Monsch, R. Postuma, 2018, Movement disorders : official journal of the Movement Disorder Society.

Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease

Nick C Fox, S. Gilman, M. Rossor, 2005, Neurology.

Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

Nick C Fox, S Gilman, N C Fox, 2005, Neurology.

BotB (botulinum Toxin type B): Evaluation of safety and tolerability in botulinum toxin type A‐Resistant cervical dystonia patients (preliminary study)

C. O’Brien, J. Wallace, M. Koller, 1997, Movement disorders : official journal of the Movement Disorder Society.

Pharmacokinetic Profile of Orally Administered Scyllo‐Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid‐Beta in Healthy Subjects

J. Cedarbaum, L. Ereshefsky, P. Garzone, 2013, Clinical pharmacology in drug development.

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.

M. Liedtke, D. Seldin, M. Gertz, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral amyloid anti-aggregating agent ELND005 is measurable in CSF and brain of healthy adult men

J. Cedarbaum, L. Ereshefsky, P. Garzone, 2009, Alzheimer's & Dementia.

Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.

M. Brin, S. Factor, C. Singer, 1999, Neurology.

Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.

J. Jankovic, M. Brin, C. Adler, 1999, Neurology.

First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers

M. Grundman, D. Schenk, W. Zago, 2016, Movement disorders : official journal of the Movement Disorder Society.

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–&agr;-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial

J. Jankovic, J. Quinn, M. Grundman, 2018, JAMA neurology.

Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia

J. Jankovic, M. Brin, D. Tarsy, 1997, Neurology.

Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction.

M. Liedtke, D. Seldin, M. Gertz, 2015 .

The VITAL Amyloidosis Study: A Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study of NEOD001 in Patients with AL Amyloidosis and Cardiac Dysfunction

M. Liedtke, M. Gertz, G. Merlini, 2016 .

Large-Scale Continuous Mobility Monitoring of Parkinson's Disease Patients Using Smartphones

Liping Jin, Detlef Wolf, Martin Koller, 2017, MobiHealth.

A neuropsychological test battery for use in Alzheimer disease clinical trials.

Martin Koller, Michael Grundman, L. Jenkins, 2007, Archives of neurology.

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data

W. Poewe, J. Sevigny, R. Doody, 2021, Frontiers in Neurology.

A safety and pharmacokinetic study of intravenous natalizumab in patients with MS

M. Koller, T. Vollmer, W. Sheremata, 1999, Neurology.

Results from a phase 1b multiple ascending-dose study of PRX002/RG7935, an Anti-alpha-synuclein monoclonal antibody, in patients with Parkinson’s disease

J. Jankovic, D. Jennings, J. Quinn, 2018 .

Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients.

C. O’Brien, J. Wallace, M. Koller, 1998, Advances in neurology.

Smartphone-based continuous mobility monitoring of Parkinsons disease patients reveals impacts of ambulatory bout length on gait features

Martin Koller, Anirvan Ghosh, Wei-Yi Cheng, 2017, 2017 IEEE Life Sciences Conference (LSC).

Reduction of Relapses in Multiple Sclerosis after Anti-Alpha4 Integrin Antibody (Natalizumab)

A. Minagar, T. Vollmer, W. Sheremata, 2000 .

Neod001 Demonstrates Cardiac and Renal Biomarker Responses in a Phase 1/2 Study in Patients With Amyloid Light Chain Amyloidosis and Persistent Organ Dysfunction

M. Liedtke, D. Seldin, M. Gertz, 2016 .

NEOD001 Demonstrates Cardiac and Renal Biomarker Responses in a Phase 1/2 Study in Patients With AL Amyloidosis and Persistent Organ Dysfunction

M. Liedtke, D. Seldin, M. Gertz, 2015 .

The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction.

M. Liedtke, D. Seldin, M. Gertz, 2015 .

AN ALTERNATIVE METHOD FOR ESTIMATING EFFICACY OF THE AN1792 VACCINE FOR ALZHEIMER DISEASE

Nick C Fox, S. Gilman, R. Black, 2007, Neurology.

O4-05-07 Neuropsychological, CSF, and neuropathological effects of A-beta immunotherapy (AN1792) of Alzheimer's disease in an interrupted trial

Nick C Fox, S. Gilman, J. Orgogozo, 2004, Neurobiology of Aging.

Human Activity Recognition from Sensor-Based Large-Scale Continuous Monitoring of Parkinson’s Disease Patients

Liping Jin, Detlef Wolf, Martin Koller, 2017, 2017 IEEE/ACM International Conference on Connected Health: Applications, Systems and Engineering Technologies (CHASE).

NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction: Results from the Expansion Cohort of a Phase 1/2 Study

E. Liu, M. Liedtke, M. Gertz, 2016 .

Organ Biomarker Responses in Patients With Light Chain Amyloidosis Treated With NEOD001 Are Independent of Previous Hematologic Response

E. Liu, M. Liedtke, M. Gertz, 2016 .

Pharmacokinetic Profile of Orally Administered Scyllo‐Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid‐Beta in Healthy Subjects

J. Cedarbaum, L. Ereshefsky, P. Garzone, 2013, Clinical pharmacology in drug development.